Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Annals of Hematology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00663015PMID 8605279
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incidence and clinical importance of perioperative histamine release: randomised study of volume loading and antihistamines after induction of anaesthesia. Trial Group Mainz/Marburg.

  1994cited by this paper
• Response to interferon alfa-2b in a patient with systemic mastocytosis.

  1992cited by this paper
• Bone mastocytosis. A report of nine cases with a bone histomorphometric study.

  1992cited by this paper
• Specific high-affinity receptors for interferon-gamma on mouse bone marrow-derived mast cells: inhibitory effect of interferon-gamma on mast cell precursors.

  1990cited by this paper
• Specific high‐affinity receptors for interferon‐γ on mouse bone marrow‐derived mast cells: inhibitory effect of interferon‐γ on mast cell precursors

  1990cited by this paper
• Reference values for trabecular and cortical vertebral bone density in single and dual-energy quantitative computed tomography.

  1989cited by this paper
• The osteoporosis of heparinotherapy and systemic mastocytosis

  1989cited by this paper
• Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption.

  1987cited by this paper
• Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.

  1986cited by this paper
• Tissue mast cells in health and disease.

  1985cited by this paper
• Systemic mast cell disease: A clinical and hematopathologic study of 26 cases

  1982cited by this paper

• Skeletal Involvement in Systemic Mastocytosis: Pathophysiology, Clinical Management, Standards of Care, and Novel Therapeutic Strategies

  2026cites this paper
• Management of Bone Health in Adult Mastocytosis

  2025cites this paper
• Management of skeletal-related events and fracture prevention in systemic mastocytosis.

  2025cites this paper
• Osteoporosis in Systemic Mastocytosis: A Scoping Review

  2024cites this paper
• Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management

  2023cites this paper
• Advanced systemic mastocytosis—Revised classification, new drugs and how we treat

  2023cites this paper
• Clinical Approach to Mast Cell Activation Syndromes: A Practical Overview Short title: Review of mast cell activation syndromes

  2021cites this paper
• Modern approaches on stem cells and scaffolding technology for osteogenic differentiation and regeneration

  2021cites this paper
• Clinical Approach to Mast Cell Activation Syndromes: A Practical Overview.

  2021cites this paper
• Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management

  2021cites this paper
• Systemic mastocytosis – a complex problem of symptomatic treatment

  2020cites this paper
• Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis

  2020cites this paper
• Bone Disease in Mastocytosis.

  2018cites this paper
• Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management

  2018cites this paper
• Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes

  2016cites this paper
• Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management

  2016cites this paper
• Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis

  2016cites this paper
• Endocrine manifestations of systemic mastocytosis in bone

  2016cites this paper
• CME Information

  2016cites this paper
• Systemic Mastocytosis: Clinical Update and Future Directions.

  2015cites this paper
• Osteoporosis and Osteopathy Markers in Patients with Mastocytosis

  2015cites this paper
• CME Information: Systemic mastocytosis in adults: 2015 update on diagnosis, risk-stratification, and management

  2015cites this paper
• Bone morbidity in chronic myeloproliferative neoplasms

  2015influential citation
• Bone involvement and osteoporosis in mastocytosis.

  2014cites this paper
• Management of adult mastocytosis

  2014cites this paper
• CME Information

  2013cites this paper
• Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population‐based cohort study

  2013cites this paper
• How I Treat How I treat patients with indolent and smoldering mastocytosis ( rare conditions but dif fi cult to manage )

  2013cites this paper
• How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage).

  2013cites this paper
• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cites this paper
• Systemic mastocytosis: disease overview, pathogenesis, and treatment.

  2012cites this paper
• Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management

  2012cites this paper
• Classical and Emerging Roles of Vitamin D in Hepatitis C Virus Infection

  2011cites this paper
• Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management

  2011cites this paper
• Continuing medical education program i n American Journal of Hematology

  2011cites this paper
• Manifestaciones óseas de las mastocitosis

  2010cites this paper
• Manifestations osseuses des mastocytoses

  2010cites this paper
• Spectrum, Function, and Value of Targets Expressed in Neoplastic Mast Cells

  2009cites this paper
• Osteoporosis como primera manifestacin de una mastocitosis sistmica. Estudio de 6 casos

  2007cites this paper
• Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia, and Mast Cell Disease

  2007cites this paper
• Ribavirin enhances osteoclast formation through osteoblasts via up-regulation of TRANCE/RANKL

  2007cites this paper
• [Osteoporosis as a first manifestation of systemic mastocytosis. Study of 6 cases].

  2007cites this paper
• Pathogenesis, clinical features, and treatment advances in mastocytosis.

  2006cites this paper
• Treatment of systemic mastocytosis.

  2006cites this paper
• Diagnostic evaluation and classification of mastocytosis.

  2006cites this paper
• Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis

  2006cites this paper
• Systemic mastocytosis: clinical manifestations and differential diagnosis.

  2006cites this paper
• Elevated Tryptase Levels Are Associated with Greater Bone Density in a Cohort of Patients with Mastocytosis

  2006cites this paper
• Systemic Mastocytosis: Bone Marrow Pathology, Classification, and Current Therapies

  2005cites this paper
• Interferon Treatment for Hypereosinophilic Syndromes and Systemic Mastocytosis

  2005cites this paper
• [Anaphylactoid reaction in occult systemic mastocytosis. A rare dermatologic emergency ].

  2005cites this paper
• Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case.

  2005cites this paper
• Mastocytosis: Pathology, genetics, and current options for therapy

  2005cites this paper
• Anaphylaktoide Reaktionen bei okkulter systemischer Mastozytose

  2005cites this paper
• Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature.

  2004cites this paper
• Successful treatment of systemic mastocytosis with high dose interferon alfa: Long-term follow-up of a case☆

  2004cites this paper
• On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts

  2004cites this paper
• Treatment of systemic mast cell disease: beyond interferon.

  2004cites this paper
• Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.

  2004cites this paper
• Management of patients with systemic mastocytosis: Review of M. D. Anderson Cancer Center experience

  2004cites this paper
• Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.

  2004influential citation
• Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria.

  2003cites this paper
• Diagnosis and treatment of systemic mastocytosis: state of the art

  2003cites this paper
• Treatment of adult systemic mastocytosis with interferon‐α: results of a multicentre phase II trial on 20 patients

  2002cites this paper
• Mastocytosis: review of clinical and experimental aspects.

  2001cites this paper
• Mastocytosis: recent advances in defining the disease

  2001cites this paper
• Diagnostic criteria and classification of mastocytosis: a consensus proposal.

  2001cites this paper
• Effects of interferon-α2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis

  2000cites this paper
• Treatment of systemic mast cell disorders.

  2000cites this paper
• Drug-Induced Bone Loss

  2000cites this paper
• [Systemic mastocytosis].

  1999cites this paper
• IFNalpha treatment in systemic mastocytosis.

  1999cites this paper
• Lymphoblastoid interferon-alpha downregulates parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor expression in human osteoblastic cells (Saos-2).

  1998cites this paper
• [Urticaria pigmentosa and mastocytosis].

  1998cites this paper
• [Mastocytosis].

  1998cites this paper
• Systemic mastocytosis with extensive polypoid lesions in the intestines; successful treatment with interferon-alpha.

  1998cites this paper
• [Interferon alpha and pamidronate: a useful combination in the treatment of osteoporosis and systemic mastocytosis].

  1998cites this paper
• Secondary osteoporosis.

  1997cites this paper
• Clinical stable systemic mastocytosis with interferon alpha 2b therapy.

  1997cites this paper